Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
$0.01
+4.0%		$0.01
$0.01
▼
$5.72
$745K0.19675,496 shs401,180 shs
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.07
-5.9%		$0.07
$0.03
▼
$0.11
$807K1.5224,947 shs90,253 shs
PainReform Ltd. stock logo
PRFX
PainReform
$0.86
-7.3%		$1.09
$0.85
▼
$7.95
$748K1.051.33 million shs88,064 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,681.48%
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
-9.09%-16.67%-6.54%-9.09%-99.80%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
+31.58%+13.64%+47.06%+44.23%-4.09%
PainReform Ltd. stock logo
PRFX
PainReform
-2.40%-5.28%-15.68%-31.80%-86.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
$0.01
+4.0%		$0.01
$0.01
▼
$5.72
$745K0.19675,496 shs401,180 shs
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.07
-5.9%		$0.07
$0.03
▼
$0.11
$807K1.5224,947 shs90,253 shs
PainReform Ltd. stock logo
PRFX
PainReform
$0.86
-7.3%		$1.09
$0.85
▼
$7.95
$748K1.051.33 million shs88,064 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,681.48%
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
-9.09%-16.67%-6.54%-9.09%-99.80%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
+31.58%+13.64%+47.06%+44.23%-4.09%
PainReform Ltd. stock logo
PRFX
PainReform
-2.40%-5.28%-15.68%-31.80%-86.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00
N/AN/AN/A
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
1.67
Reduce$30.00288,361.54% Upside
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.00
N/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest AMPE, PRFX, HEPA, and CERO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
PainReform Ltd. stock logo
PRFX
PainReform
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/A$4.04 per shareN/A
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/AN/AN/AN/A($41.98) per shareN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/A$1.29 per shareN/A
PainReform Ltd. stock logo
PRFX
PainReform
$20K37.41N/AN/A$23.07 per share0.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
-$8.63M-$11.01N/AN/AN/AN/AN/AN/AN/A
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
-$8.30M-$9.84N/AN/AN/AN/AN/A-209.40%N/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$48.93M-$72.15N/AN/AN/AN/A-812.56%-207.31%10/14/2026 (Estimated)
PainReform Ltd. stock logo
PRFX
PainReform
-$5.02M-$736.66N/AN/AN/AN/AN/AN/AN/A

Latest AMPE, PRFX, HEPA, and CERO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/3/2026Q2 2026
PainReform Ltd. stock logo
PRFX
PainReform
N/A-$1.13N/A-$1.1250N/A$0.01 million
8/13/2026Q2 2026
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$200.00-$0.08+$199.92N/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/A
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/AN/AN/AN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/A
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/A
0.56
0.56
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/A
1.30
1.30
PainReform Ltd. stock logo
PRFX
PainReform
N/A
5.07
1.78

Institutional Ownership

CompanyInstitutional Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
5.73%
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
29.64%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
17.24%
PainReform Ltd. stock logo
PRFX
PainReform
37.28%

Insider Ownership

CompanyInsider Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
3.30%
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
0.36%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.06%
PainReform Ltd. stock logo
PRFX
PainReform
34.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
201.14 million1.10 millionNo Data
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
871.63 million1.05 millionN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
2011.44 million6.63 millionNo Data
PainReform Ltd. stock logo
PRFX
PainReform
4870,000570,000Not Optionable

Recent News About These Companies

PainReform Ltd. (NASDAQ:PRFX) Sees Significant Decrease in Short Interest
September 11 at 3:40 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31016917
PRF Technologies to Establish GridFeed™ as a Standalone Subsidiary to Pursue Strategic Alliances for Its AI-Driven Renewable Energy Trading Platform
September 9 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3358645/0/en/prf-technologies-to-establish-gridfeed-as-a-standalone-subsidiary-to-pursue-strategic-alliances-for-its-ai-driven-renewable-energy-trading-platform.html
PRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy Business
September 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3355915/0/en/prf-technologies-provides-first-half-2026-business-update-highlighting-significant-progress-across-healthcare-and-ai-energy-business.html
PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms
July 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/27/3333512/0/en/prf-technologies-issues-letter-to-shareholders-highlighting-strengthened-financial-position-and-building-momentum-across-its-biotechnology-and-ai-driven-energy-platforms.html
PRF Technologies to Showcase GridFeed™ at Energy Trading Week Europe 2026
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330457/0/en/prf-technologies-to-showcase-gridfeed-at-energy-trading-week-europe-2026.html
PRF Technologies Expands DeepSolar Predict™ Platform with Battery-to-Revenue Intelligence, Extending AI-Driven Revenue Optimization Across Solar and Energy Storage Assets
July 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3327824/0/en/prf-technologies-expands-deepsolar-predict-platform-with-battery-to-revenue-intelligence-extending-ai-driven-revenue-optimization-across-solar-and-energy-storage-assets.html
PRF Technologies' DeepSolar Successfully Validates Predict™ AI Platform for Renewable Energy Revenue Optimization Using Real-World European Market Data
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324076/0/en/prf-technologies-deepsolar-successfully-validates-predict-ai-platform-for-renewable-energy-revenue-optimization-using-real-world-european-market-data.html
PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark
June 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/25/3317531/0/en/prf-technologies-reports-expanded-preclinical-results-for-prf-110-in-head-to-head-comparison-with-approved-benchmark.html
PainReform Shareholders Approve All Proposals at Adjourned 2026 Annual Meeting
June 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PRFX/pressreleases/36936522/painreform-shareholders-approve-all-proposals-at-adjourned-2026-annual-meeting/
PRF Technologies Advances DeepSolar Predict™ Toward Commercial Launch as AI Platform Targets Revenue Optimization Across Renewable Energy Markets
May 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/28/3302841/0/en/prf-technologies-advances-deepsolar-predict-toward-commercial-launch-as-ai-platform-targets-revenue-optimization-across-renewable-energy-markets.html
PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study
May 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/26/3301087/0/en/prf-technologies-announces-prf-110-demonstrated-sustained-72-hour-analgesic-activity-comparable-to-approved-commercially-available-benchmark-in-head-to-head-preclinical-study.html
PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3282536/0/en/prf-technologies-announces-fda-clearance-of-ind-application-for-ocuring-k-phase-ii-clinical-trial.html
PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms
March 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/27/3263728/0/en/prf-technologies-provides-year-end-2025-business-update-highlighting-strategic-progress-across-healthcare-and-ai-driven-solar-platforms.html
PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements
March 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/17/3257187/0/en/prf-technologies-ltd-announces-commercial-collaboration-agreement-with-blade-ranger-to-accelerate-large-scale-deepsolar-commercial-engagements.html
PRF Technologies’ DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy
February 18, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/prf-technologies-deepsolar-announces-its-first-commercial-due-diligence-engagement-with-edf-power-solutions-israel-a-global-leader-in-renewable-energy-1035840319
PRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy
February 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/18/3240327/0/en/prf-technologies-deepsolar-announces-its-first-commercial-due-diligence-engagement-with-edf-power-solutions-israel-a-global-leader-in-renewable-energy.html
PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base
February 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/11/3236284/0/en/prf-technologies-wins-another-european-utility-scale-solar-deployment-expanding-deepsolar-s-installed-commercial-base.html
PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy
January 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/20/3221829/0/en/prf-technologies-files-its-first-patent-application-for-solar-plant-micro-climate-forecast-modeling-designed-to-improve-energy-production-forecast-accuracy.html
PainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy Push
January 16, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/01/49970381/painreform-stock-spikes-as-it-rebrands-expands-beyond-pharma-with-ai-clean-energy-push
PainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy Push
January 16, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/01/49970381/painreform-stock-spikes-as-it-rebrands-expands-beyond-pharma-with-ai-clean-energy-push?utm_source=snapi

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ampio Pharmaceuticals stock logo

Ampio Pharmaceuticals NYSE:AMPE

$0.18 0.00 (0.00%)
As of 09/10/2026

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

CERo Therapeutics stock logo

CERo Therapeutics NASDAQ:CERO

$0.01 +0.00 (+4.00%)
As of 02:49 PM Eastern

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Hepion Pharmaceuticals stock logo

Hepion Pharmaceuticals NASDAQ:HEPA

$0.07 0.00 (-5.87%)
As of 03:53 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

PainReform stock logo

PainReform NASDAQ:PRFX

$0.86 -0.07 (-7.27%)
Closing price 04:00 PM Eastern
Extended Trading
$0.90 +0.04 (+5.10%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas